Description
A potent and selective inhibitor of GSK3 (IC50s = 1.5 and 0.9 for human recombinant GSK3α and GSK2β, respectively); has >10-fold selectivity for GSK3 against a panel of 40 kinases at a concentration of 20 μM; induces time-dependent stabilization of β-catenin total protein and activates Wnt signaling in vitro; has potent antiproliferative activity in BRAF wild-type/NRAS mutant and BRAF mutant melanoma cell lines (IC50s = 6.0-11.8 nM) but has limited to no activity in non-melanoma cell lines (IC50s = 430 to >20,000 nM); knockdown of β-catenin in A375 and M14 melanoma cells induces LY2090314 resistance in vitro; reduces tumor volume in a murine A375 xenograft model as a single agent and synergizes with decabarzine for a greater antitumor effect,
Formal name: 3-[9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-a]pyridin-3-yl-1H-pyrrole-2,5-dione
Synonyms:
Molecular weight: 512.5
CAS: 603288-22-8
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|GSK3||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|GSK3 Signaling||Research Area|Cancer|Cell Signaling|Wnt Signaling||Research Area|Cell Biology|Cell Signaling|Wnt Signaling